Companies commercializing cell and gene therapies face many novel challenges, including: supply chain logistics, patient access, adherence, outcomes collection, and data analysis. Layne reviews the crucial issues and explains the services needed for success.
McKesson Life Sciences has developed a portfolio of patient-centric solutions to help cell and gene therapy companies. To learn more, download their new white paper: The Key to Commercializing Revolutionary Gene Therapies and Other Orphan Drugs.
Read on for Layne’s insights.
Commercializing Cell and Gene Therapies with High-Touch Services
By Layne Martin, VP/GM, Specialty Distribution and Third-Party Logistics, McKesson Life Sciences
In light of the complex handling, storage, transportation and administration requirements of these innovative therapies, cell and gene therapy manufacturers need real-time, end-to-end visibility and control over the distribution channel to maintain the integrity of the product and avoid delays in starting treatment.
In addition to optimizing supply chain logistics, these companies must employ a commercial strategy that leverages high-touch solutions to optimize and enhance the patient-provider journey and experience. Educating patients, providers and caregivers on what to expect of CAR-T therapies and how to deal with the intricacies of their care end to end is a critical part of the commercialization strategy. Patients need to understand each step in the therapy process, from the first blood draw to post-treatment monitoring.
[Click to Enlarge]
Another important aspect of commercialization is maintaining visibility into the patients’ treatment journey and monitoring for clinical data points and safety signals. The ability to monitor these patients in the real-world setting will allow cell and gene therapy companies to deliver targeted interventions throughout the treatment journey, as well as educate providers on how to care for their patients throughout each unique treatment protocol.
Observational studies using real-world evidence (RWE) provide significant opportunities to gain a comprehensive view of patient outcomes, including confirming durability of the therapy, identifying long-term safety issues and supporting reimbursement and value-based care strategies.
Thus, to ensure the successful commercialization of cell and gene therapies, biopharma companies will require a partner that:
- Provides superior connectivity and coordination between patients, providers and payers
- Can educate all stakeholders as they navigate through the complex therapy manufacturing and administration process
- Has the infrastructure to manage the financial transactions supporting these higher-priced therapies
To learn more, visit McKesson Life Sciences or email LifeSciences@mckesson.com.
Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. These posts do not necessarily reflect our opinions and should not be considered endorsements.
To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (firstname.lastname@example.org).